NEW YORK (GenomeWeb News) – Atossa Genetics today announced it has entered into a contract with preferred provider organization FedMed, giving its members access to Atossa's breast health tests.
FedMed has more than 550,000 providers in its network, including 4,000 hospitals, and more than 60,000 ancillary facilities. It serves more than 40 million Americans.
Among the tests offered by Seattle-based Atossa, which went public in November, are the ForeCYTE Breast Health Test, a risk stratification test for breast cancer, and the ArgusCYTE Breast Health Test for monitoring patients for the potential recurrence of breast cancer.
The agreement with FedMed will provide patients and doctors greater access to Atossa's tests and help fill "a significant unmet clinical need in the medical community for more effective ways to identify women at high risk of breast cancer," Atossa Chairman, President, and CEO Steven Quay said in a statement.
In September, the company signed a deal with managed healthcare plan MultiPlan giving its providers and patients access to Atossa's tests.